Clinical Trials Logo

Clinical Trial Summary

This study aims to compare the pharmacokinetics of naloxone when administered as the Mitovie nasal spray (Test Product) and as a solution for injection (Comparator Product) administered intranasally using a mucosal atomization device (MAD).


Clinical Trial Description

Naloxone hydrochloride is currently only recommended and licensed for intravenous, intramuscular and subcutaneous administration. It has also been used by intranasal administration (off-label use) when the intravenous route is not suitable by administering the Solution for Injection using a mucosal atomization device (MAD). However, due to the volume of naloxone solution administered this way, some of it may be inadvertently swallowed and not absorbed into the nasal mucosa and the product requires administration by medically trained personnel. The study aims to investigate intranasal administration of naloxone using a more concentrated solution and a nasal delivery device. ;


Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01622504
Study type Interventional
Source Mitovie Pharma Ltd
Contact Rana Hassan, MSc
Phone +96265627651
Email r.hassan@iprc.com.jo
Status Not yet recruiting
Phase Phase 1
Start date June 2012
Completion date August 2012

See also
  Status Clinical Trial Phase
Completed NCT04372238 - The Rhode Island Prescription and Illicit Drug Study N/A
Recruiting NCT03924505 - Preventing Opioid Overdose Mortality in the United States N/A
Completed NCT05093309 - Preventing Opioid Overdose Deaths by Empowering Pharmacists to Dispense Naloxone N/A
Completed NCT05219669 - Pharmacokinetic Evaluation of Intranasal Nalmefene Using Three Dosing Regimens Phase 1
Completed NCT04317053 - Multi-Center Randomized Controlled Trial of Relay- NYC's Nonfatal Overdose Response Program Phase 3
Not yet recruiting NCT06466005 - UnityPhilly Response App for Overdose Reversal
Recruiting NCT04815590 - Extended-release Injectable Buprenorphine for Individuals at High Risk of Overdose
Active, not recruiting NCT05096429 - Preventing Overdose Using Information and Data From the Environment N/A
Suspended NCT05114460 - Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal Phase 2
Recruiting NCT06238128 - Opioid Rapid Response System: Naloxone Training in Communities N/A
Completed NCT02662153 - Incidence and Predictors of Opioid Overdose and Death Among Long-Term Users of Opioid Analgesics
Active, not recruiting NCT05944133 - Health Insurance Instability and Mortality Among Patients Receiving Bup Tx for OUD
Completed NCT05377255 - Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults Phase 1
Recruiting NCT05877118 - Improving Availability of Intranasal Naloxone N/A
Recruiting NCT05072249 - European Cohort Study of the Effectiveness of Take Home Naloxone
Withdrawn NCT05808881 - Clinical Outcomes From Nalmefene Phase 4
Not yet recruiting NCT06429436 - Vending Machine Naloxone Distribution for Your Community (VENDY) Phase 4
Completed NCT05506267 - Development of a Tracheal Sound Sensor
Completed NCT02535494 - Risks and Benefits of Naloxone Prescribing N/A
Not yet recruiting NCT06408714 - Nalmefene vs Naloxone for the Treatment of Recurrent Respiratory Depression After Opioid Overdose Phase 3